Kodiak Sciences Inc. is a biopharmaceutical company developing next-generation therapies for ophthalmic diseases, specifically targeting retinal vascular diseases and macular edema. Founded in 2009, the company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to create intravitreal biologics with extended ocular half-lives. Its lead investigational medicine, tarcocimab tedromer (Zenkuda), is an anti-VEGF therapy being developed for diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The pipeline also includes KSI-501, an anti-IL-6/VEGF bispecific therapy, and KSI-101, a bispecific protein targeting IL-6 and VEGF for macular edema secondary to inflammation. Kodiak is advancing its platform technology to embed small molecules into its biopolymer backbone, known as the ABCD platform, for potential applications in glaucoma and geographic atrophy. The company operates a dedicated commercial-scale drug substance manufacturing facility named Ursus, built in collaboration with Lonza. Kodiak retains all global rights to its product candidates and intends to commercialize its therapies in major markets.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage kodiak.com
Sector Healthcare IR page ir.kodiak.com
Tags
ophthalmology, retinal diseases, anti-vegf therapy, antibody biopolymer conjugates, intravitreal injection, diabetic retinopathy, wet amd, macular edema, bispecific antibodies, drug delivery, Zenkuda, tarcocimab tedromer, KSI-301, KSI-501, KSI-101, ABC platform, ABCD platform, Ursus, Lonza, GLOW1, GLOW2, BEACON, DAYLIGHT, DAYBREAK, GLEAM, GLIMMER, DAZZLE, APEX, PEAK, PINNACLE
Press page —

Metrics

Valuation  
Market cap $ 6.335B
Market cap (USD) $ 6.335B
P/E -24.14
PEG —
P/BV 503.89
P/S —
P/OCF -37.38
P/FCF -36.66
Dividend yield —
Turnover / mcap —
Returns  
ROE -149.5%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score -72.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Assets 351.533M 335.578M 479.372M 666.628M 904.22M 1.067B 358.866M 92.189M 3.244M
Net profit -229.967M -176.207M -260.491M -333.823M -266.99M -133.096M -47.365M -41.443M -27.936M
Free cash flow -136.514M -117.694M -195.533M -243.48M -199.302M -87.242M -39.583M -29.109M -17.864M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 27.96 9.95 3.04 7.16 84.78 146.91 71.95 7.1 —
Price performance 12m 1.81 2.27 -0.58 -0.92 -0.42 1.04 9.13 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 1.94M 77.4M 80M 87.7M 81.6M 70.3M 59.2M
Cash and deposits (USD) 9.62M 1.4M 88.3M 212M 944M 732M 190M 286M 168M 210M
Right-of-use assets (USD) — — — 1.79M 73.7M 66.7M 59.4M 54.5M 46.5M 36.6M
Cash flow detail
Operating cash flow (USD) -16M -17.7M -29M -39.1M -83.4M -182M -206M -154M -117M -136M
Purchases of property, plant and equipment (USD) -771,000 -209,000 -78,000 -437,000 -3.81M -17M -37M -41.4M -375,000 -506,000
Change in payables (cash effect) (USD) 23,000 2.28M -2.32M 1.57M 5.22M -2.09M 1.66M 5.6M -9.69M 8.07M
Share buybacks (cash effect) (USD) -4,000 0.00 0.00 — — — — — — —
Interest paid (cash effect) (USD) -6,000 -24,000 -19,000 -8,000 -25,000 -22,000 -18,000 -13,000 0.00 0.00
Income taxes paid (cash effect) (USD) — — — — — — — 0.00 0.00 0.00
Share-based compensation (USD) 272,000 275,000 2.67M 6.11M 30.7M 6.14M 106M 88.6M 60.2M 58.9M
Free cash flow (OCF - PPE - intangibles) (USD) -16.8M -17.9M -29.1M -39.6M -87.2M -199M -243M -196M -118M -137M
Income detail
Research and development expense (USD) 14.1M 22M 18.8M 37.5M 107M 217M 268M 206M 126M 182M
↳ 5y CAGR +72.9% +64.8% +61.5% +27.4% +11.2%
Total comprehensive income (USD) — -27.9M -41.4M -47.4M -133M -267M -335M -259M -176M -230M
Comprehensive income to owners (USD) — -27.9M -41.4M -47.4M -133M -267M -335M -259M -176M -230M
Reported Mar 27, 2019 Mar 16, 2020 Mar 16, 2020 Mar 16, 2020 Mar 1, 2021 Mar 1, 2022 Mar 28, 2023 Mar 31, 2026 Mar 31, 2026 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PALO ALTO, Calif., November 12, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2026.

“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company,” said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. “The DAYBREAK results reinforce Zenkuda’s potential to become a first-line therapy in wet AMD, combining rapid disease control with a 24-week dosing interval for the majority of patients under strict treat-to-dry and maintain dry criteria reflective of real-world clinical practice. Tabirafusp-ted has delivered a positive Phase 3 readout in wet AMD and is actively enrolling in our Phase 3 ALTO study in diabetic macular edema. And KSI-101 is rapidly approaching its first pivotal readout in macular edema secondary to inflammation, a patient population with severe disease and no approved intravitreal biologic therapy.

October 7, 2026 at 7:00 AM EDT

Download PDF

First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026.

Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

PALO ALTO, Calif., Oct. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).

The presentations will include the first scientific presentation of results from the pivotal Phase 3 DAYBREAK study of Zenkuda and tabirafusp-ted in patients with wet age-related macular degeneration (wet AMD), as well as Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

At AAO 2026, Charles Wykoff, M.D., Ph.D., will present the DAYBREAK results during Retina Subspecialty Day on Friday, October 9, 2026. Kodiak announced topline results from DAYBREAK on September 28, 2026. The study met its primary endpoint for each investigational treatment, with both Zenkuda and tabirafusp-ted demonstrating non-inferior vision gains compared with aflibercept at Year 1.

American Academy of Ophthalmology (AAO) 2026 – New Orleans; October 9-12, 2026

The following presentations will be held during Retina Subspecialty Day at AAO 2026. This will be the first scientific presentation of the Phase 3 DAYBREAK results in wet AMD.

Title: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Wet Age-related Macular Degeneration: First-time One-year Primary Efficacy and Safety Outcomes of the Phase 3 DAYBREAK Study Presenter: Charles Wykoff, M.D., Ph.D., Chairman of Research at Retina Consultants of Texas and Professor of Clinical Ophthalmology and Deputy Chair of Ophthalmology at the Blanton Eye Institute, Houston Methodist Hospital Session: Section X, Clinical Trial Updates, Part I Date and time: Friday, October 9, 2026, at 4:40 PM CT Location: New Orleans Theater

Title: GLOW2 Study: Phase 3 Study of Tarcocimab for Diabetic Retinopathy Presenter: Margaret Chang, M.D., M.S. Retina Consultants Medical Group, Sacramento, U.S. Session: Section XIX: Clinical Trial Updates, Part II Date and time: Saturday, October 10, 2026, at 4:51 PM CT Location: New Orleans Theater

The following clinical presentation will be held during Uveitis Subspecialty Day at AAO 2026.

Title: APEX Study Results: Intravitreal KSI-101 for Macular Edema Secondary to Inflammation **Presenter:**Edmund Tsui, M.D., M.S., FARVO, Associate Professor of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at UCLA Session: Section VIII: A Uveitis Lagniappe: Late Breaking Topics Date and time: Friday, October 9, 2026, at 4:20 PM CT Location: Room 271 - 273

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.

Kodiak®, Kodiak Sciences®, ABC®, ABC Platform™, Zenkuda™, VETi™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Cision View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-clinical-data-across-all-three-late-stage-programs-at-aao-2026-302900540.html

SOURCE Kodiak Sciences Inc.

John Borgeson, Chief Financial Officer, Tel (650) 281-0850, [email protected]

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

• Post-hoc analyses to identify which treatment naïve wAMD patient sub-groups can benefit from IL-6 inhibition are planned. Tabirafusp-ted development program is accelerating in diabetic macular edema and actively enrolling in the ALTO Phase 3 Study

• Zenkuda and tabirafusp-ted demonstrated safety consistent with the established safety profile of aflibercept

PALO ALTO, Calif., September 28, 2026 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration (wAMD). The DAYBREAK study in wAMD demonstrated that both Zenkuda and tabirafusp-ted achieved non-inferiority in vision gains compared to aflibercept at year one.

In DAYBREAK, Zenkuda demonstrated strong immediacy of clinical effect, matching and/or exceeding that of the aflibercept comparator through the loading phase.

Prompts

Kodiak Sciences Inc (ticker KOD), listed in United States.

Company History

Date Change Detail
Mar 24, 2016 Renamed Oligasis, LLC → KODIAK SCIENCES INC.

ETFs Holding Kodiak Sciences Inc

ETF Weight in ETF Shares Market value As of
HRTS 2.23% 33,234 $ 1.241M Aug 31, 2026
TMED 0.36% 2,147 $ 83.647K Jun 30, 2026
FSML 0.19% 6,000 $ 233.76K Jun 30, 2026
FSEG 0.15% 215 $ 8,376.40 Jun 30, 2026
TMSL 0.12% 82,979 $ 3.233M Jun 30, 2026
FESM 0.11% 159,905 $ 6.23M Jun 30, 2026
VFMO 0.10% 50,281 $ 1.878M Aug 31, 2026
RESM 0.07% 68 $ 2,649.28 Jun 30, 2026
FSEV 0.04% 70 $ 2,727.20 Jun 30, 2026
DFAS 0.02% 58,392 $ 6.321M Nov 12, 2026
MSSM 0.01% 2,058 $ 76.866K Aug 31, 2026
DXUV 0.00% 4 $ 433.00 Nov 12, 2026
NTRL short 0.00% -1,246 $ 0.00 Nov 16, 2026